Jia Shi Tang Pharmaceutical Co., Ltd.
Announcement on Progress of Equity Change Upon Receiving Approval from State-owned Assets Supervision Department and Signing of Supplementary Agreement by Shareholders
The Company and the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
Special Reminder:
-
This equity change involves the transfer of 83,057,236 shares (accounting for 28.48% of the total share capital) held by China Everbright Medical Health Industry Co., Ltd. (hereinafter referred to as "Everbright Health") and China Everbright Industrial (Group) Co., Ltd. (hereinafter referred to as "Everbright Industrial") (collectively referred to as "Everbright") in Jia Shi Tang Pharmaceutical Co., Ltd. (hereinafter referred to as "Jia Shi Tang," "the Company," or "the listed company") to China Beijing Tongrentang (Group) Co., Ltd. (hereinafter referred to as "Tongrentang Group").
-
After this equity change, Tongrentang Group will become the controlling shareholder of the Company, and the Beijing Municipal People's Government State-owned Assets Supervision and Administration Commission (hereinafter referred to as "Beijing SASAC") will become the actual controller of the Company.
-
This transaction does not trigger a mandatory takeover offer, nor does it constitute a related-party transaction. It will not adversely affect the Company's normal production and operation, does not harm the interests of the Company and its minority shareholders, and does not violate any relevant commitments.
-
This equity change is subject to the confirmation of compliance from the Shenzhen Stock Exchange before the share transfer registration procedures can be handled at the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited. There is still uncertainty, and investors are advised to pay attention to investment risks.